The role of MRPL45 and OXA1L in human mitochondrial protein synthesis

Autor: Mai, Nicole

Mitochondria produce 90% of the adenosine triphosphate (ATP) used by eukaryotic cells as a source of energy. ATP synthesis is carried out by the oxidative phosphorylation (OXPHOS) system whose components are partially-encoded by mitochondrial DNA and

Externí odkaz: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.728310

Aggression und Gewalt im ambulanten Dienst

Autor: Mai, Nicole

Publikováno v: Pflegezeitschrift: Fachzeitschrift für stationäre und ambulante Pflege; July 2022, Vol. 75 Issue: 8 p28-31, 4p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

OXA1L mutations cause mitochondrial encephalopathy and a combined oxidative phosphorylation defect.

Autor: Thompson K; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK., Mai N; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK., Oláhová M; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK., Scialó F; Institute for Cell and Molecular Biosciences, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK., Formosa LE; Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Vic., Australia., Stroud DA; Department of Biochemistry and Molecular Biology and The Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Vic., Australia., Garrett M; Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Vic., Australia., Lax NZ; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK., Robertson FM; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK., Jou C; Pathology Department, Hospital Sant Joan de Déu, CIBERER, Barcelona, Spain., Nascimento A; Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, CIBERER - ISCIII, Barcelona, Spain., Ortez C; Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, CIBERER - ISCIII, Barcelona, Spain., Jimenez-Mallebrera C; Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, CIBERER - ISCIII, Barcelona, Spain., Hardy SA; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK., He L; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK., Brown GK; Oxford Medical Genetics Laboratories, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Marttinen P; Institute of Biotechnology, University of Helsinki, Helsinki, Finland., McFarland R; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK., Sanz A; Institute for Cell and Molecular Biosciences, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK., Battersby BJ; Institute of Biotechnology, University of Helsinki, Helsinki, Finland., Bonnen PE; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA., Ryan MT; Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Vic., Australia., Chrzanowska-Lightowlers ZM; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK., Lightowlers RN; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK., Taylor RW; Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, UK robert.taylor@ncl.ac.uk.

Publikováno v: EMBO molecular medicine [EMBO Mol Med] 2018 Nov; Vol. 10 (11).